Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines

PHASE2CompletedINTERVENTIONAL
Enrollment

352

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Glabellar Frown Lines
Interventions
BIOLOGICAL

Botulinum purified neurotoxin, Type A

The subject is to be injected intra-muscularly into a total of five sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim. Each site is injected with 0.1 ml (4U), for a total of 20 U and 0.5 ml.

Trial Locations (1)

90404

ATS Clinical Research, Santa Monica

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Evolus, Inc.

INDUSTRY

NCT02184988 - Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines | Biotech Hunter | Biotech Hunter